The rigid amphipathic fusion inhibitor dUY11 acts through photosensitization of viruses

Journal of Virology

Volumn 88, Issue 3, 2014, Pages 1849-1853

  Vigant, Frederic ^a   Hollmann, Axel ^b   Lee, Jihye ^a   Santos, Nuno C ^b   Jung, Michael E ^a   Lee, Benhur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RIGID AMPHIPATHIC FUSION INHIBITOR DUY11; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG MECHANISM; HERPES SIMPLEX VIRUS 1; LIPID COMPOSITION; LIPID OXIDATION; LIPOPHILICITY; NONHUMAN; PHOTOSENSITIZATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS ENVELOPE;

ANTIVIRAL AGENTS; CELL MEMBRANE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; LIGHT; VIRUS INTERNALIZATION;

EID: 84892460793     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02907-13     Document Type: Article

References (27)

1. Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV. 2008. A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 105:3088-3093. http://dx.doi.org/10.1073/pnas.0712380105.
2. Chernomordik LV, Vogel SS, Sokoloff A, Onaran HO, Leikina EA, Zimmerberg J. 1993. Lysolipids reversibly inhibit Ca(2+)-, GTP-and pH-dependent fusion of biological membranes. FEBS Lett. 318:71-76. http://dx.doi.org/10.1016/0014-5793(93)81330-3.
3. Colpitts CC, Ustinov AV, Epand RF, Epand RM, Korshun VA, Schang LM. 2013. 5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses. J. Virol. 87:3640-3654. http://dx.doi.org/10.1128/JVI.02882-12.
4. Katz DH, Marcelletti JF, Pope LE, Khalil MH, Katz LR, McFadden R. 1994. n-Docosanol: broad spectrum anti-viral activity against lipidenveloped viruses. Ann. N. Y. Acad. Sci. 724:472-488. http://dx.doi.org/10.1111/j.1749-6632.1994.tb38949.x.
5. Soares MM, King SW, Thorpe PE. 2008. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 14:1357-1362. http://dx.doi.org/10.1038/nm.1885.
6. St. Vincent MR, Colpitts CC, Ustinov AV, Muqadas M, Joyce MA, Barsby NL, Epand RF, Epand RM, Khramyshev SA, Valueva OA, Korshun VA, Tyrrell DL, Schang LM. 2010. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc. Natl. Acad. Sci. U.S.A. 107:17339-17344. http://dx.doi .org/10.1073/pnas.1010026107.
7. Stiasny K, Heinz FX. 2004. Effect of membrane curvature-modifying lipids on membrane fusion by tick-borne encephalitis virus. J. Virol. 78: 8536-8542. http://dx.doi.org/10.1128/JVI.78.16.8536-8542.2004.
8. Vigant F, Lee J, Hollmann A, Tanner LB, Akyol Ataman Z, Yun T, Shui G, Aguilar HC, Zhang D, Meriwether D, Roman-Sosa G, Robinson LR, Juelich TL, Buczkowski H, Chou S, Castanho MA, Wolf MC, Smith JK, Banyard A, Kielian M, Reddy S, Wenk MR, Selke M, Santos NC, Freiberg AN, Jung ME, Lee B. 2013. A mechanistic paradigm for broadspectrum antivirals that target virus-cell fusion. PLoS Pathog. 9:e1003297. http://dx.doi.org/10.1371/journal.ppat.1003297.
9. Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, Li J, Watson NF, Fang AQ, Aguilar HC, Porotto M, Honko AN, Damoiseaux R, Miller JP, Woodson SE, Chantasirivisal S, Fontanes V, Negrete OA, Krogstad P, Dasgupta A, Moscona A, Hensley LE, Whelan SP, Faull KF, Holbrook MR, Jung ME, Lee B. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. U.S.A. 107:3157-3162. http://dx.doi.org/10.1073/pnas.0909587107.
10. Zasloff M, Adams AP, Beckerman B, Campbell A, Han Z, Luijten E, Meza I, Julander J, Mishra A, Qu W, Taylor JM, Weaver SC, Wong GC. 2011. Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential. Proc. Natl. Acad. Sci. U.S.A. 108:15978-15983. http://dx.doi.org/10.1073/pnas.1108558108.
11. Melikyan GB. 2010. Driving a wedge between viral lipids blocks infection. Proc. Natl. Acad. Sci. U.S.A. 107:17069-17070. http://dx.doi.org/10.1073/pnas.1012748107.
12. Song JM, Seong BL. 2010. Viral membranes: an emerging antiviral target for enveloped viruses? Expert Rev. Anti Infect. Ther. 8:635-638. http://dx .doi.org/10.1586/eri.10.51.
13. Vigant F, Jung M, Lee B. 2010. Positive reinforcement for viruses. Chem. Biol. 17:1049-1051. http://dx.doi.org/10.1016/j.chembiol.2010.10.002.
14. Wojcechowskyj JA, Doms RW. 2010. A potent, broad-spectrum antiviral agent that targets viral membranes. Viruses 2:1106-1109. http://dx.doi .org/10.3390/v2051106.
15. Costa L, Faustino MAF, Neves MGPMS, Cunha A, Almeida A. 2012. Photodynamic incativation of mammalian viruses and bacteriophages. Viruses 4:1034-1074. http://dx.doi.org/10.3390/v4071034.
16. Chotimarkorn C, Nagasaka R, Ushio H, Ohshima T, Matsunaga S. 2005. Development of novel fluorescent probe 3-perylene diphenylphosphine for determination of lipid hydroperoxide with fluorescent image analysis. Biochem. Biophys. Res. Comm. 338:1222-1228. http://dx.doi .org/10.1016/j.bbrc.2005.10.060.
17. Hirayama J, Ikebuchi K, Abe H, Kwon KW, Ohnishi Y, Horiuchi M, Shinagawa M, Ikuta K, Kamo N, Sekiguchi S. 1997. Photoinactivation of virus infectivity by hypocrellin A. Photochem. Photobiol. 66:697-700. http://dx.doi.org/10.1111/j.1751-1097.1997.tb03209.x.
18. Olivo M, Chin WLW. 2006. Perylenequinones in photodynamic therapy: cellular versus vascular response. J. Environ. Pathol. Toxicol. Oncol. 25:223-237. http://dx.doi.org/10.1615/JEnvironPatholToxicolOncol.v25.i1-2.140.
19. Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T. 2009. Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med. Sci. 24:259-268. http://dx.doi.org/10.1007/s10103-008-0539-1.
20. Fernandez JM, Bilgin MD, Grossweiner LI. 1997. Singlet oxygen generation by photodynamic agents. J. Photochem. Photobiol. B Biol. 37:131-140. http://dx.doi.org/10.1016/S1011-1344(96)07349-6.
21. Stachowiak JC, Brodsky FM, Miller EA. 2013. A cost-benefit analysis of the physical mechanisms of membrane curvature. Nat. Cell Biol. 15:1019-1027. http://dx.doi.org/10.1038/ncb2832.
22. Lentz BR. 1993. Use of fluorescent-probes to monitor molecular order and motions within liposome bilayers. Chem. Phys. Lipids 64:99-116. http://dx.doi.org/10.1016/0009-3084(93)90060-G.
23. Idris NM, Gnanasammandhan MK, Zhang J, Ho PC, Mahendran R, Zhang Y. 2012. In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. Nat. Med. 18:1580-1585. http://dx.doi.org/10.1038/nm.2933.
24. Kharkwal GB, Sharma SK, Huang YY, Dai TH, Hamblin MR. 2011. Photodynamic therapy for infections: clinical applications. Lasers Surg. Med. 43:755-767. http://dx.doi.org/10.1002/lsm.21080.
25. Santos NC, Prieto M, Castanho MA. 1998. Interaction of the major epitope region of HIV protein gp41 with membrane model systems. A fluorescence spectroscopy study. Biochemistry 37:8674-8682.
26. Evans E, Rawicz W. 1990. Entropy-driven tension and bending elasticity in condensed-fluid membranes. Phys. Rev. Lett. 64:2094-2097. http://dx .doi.org/10.1103/PhysRevLett.64.2094.
27. Rawicz W, Olbrich KC, McIntosh T, Needham D, Evans E. 2000. Effect of chain length and unsaturation on elasticity of lipid bilayers. Biophys. J. 79:328-339. http://dx.doi.org/10.1016/S0006-3495(00)76295-3.